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ABSTRACT
Infectious and parasitic diseases affecting women during their reproductive age may result in vertical 
transmission. The aim of this study was to determine the seroprevalence for TORSCH among preg-
nant women receiving care at a university hospital. Records of 574 pregnant women who received 
medical attention from January 2006 to December 2007 were assessed. The mean age was 27.2 ± 6.5 
years ranging from 13 to 44. The results of the immunodiagnostic tests were: 62.0% (345/556) for 
IgG and 3.4% (19/556) for IgM anti-T. gondii; 93.1% (433/465) for IgG and 0.6% (3/465) for IgM 
anti-rubella; 0.9% (5/561) for VDRL; 1.8% (10/554) for HBsAg; 0.7% (4/545) for anti-HCV and 
2.1% (11/531) for HIV. In conclusion, the results of immunodiagnostic tests for the TORSCH panel 
among pregnant women attending a perinatal service of a university hospital are in agreement with 
those reported by previous studies and by governmental sources.
Keywords: toxoplasmosis; rubella; infectious disease transmission; vertical; pregnancy complica-
tions; infectious; hepatitis.
[Braz J Infect Dis 2010;14(6):601-605]©Elsevier Editora Ltda.
INTRODUCTION
Infectious and parasitic diseases affect-
ing pregnant women are a potential public 
health problem, as they may cause congenital 
abnormalities or be vertically transmitted.1,2 
The prevalence rates of these diseases are 
frequently associated with the pregnancy pe-
riod. The risks are associated with their high-
er rates in less well educated populations.3 
Knowledge of the prevalence and incidence 
of these infectious-parasitic diseases in preg-
nant women is of great importance in the 
planning of maternal-fetal health programs 
strategies, screening and treatment of these 
diseases.4
Serological tests to diagnose infections of 
the TORSCH (Toxoplasmosis, Rubella, Syph-
ilis, Cytomegalovirus, Hepatitis B and C, 
and HIV) are mandatory, as they pose a po-
tential life threatening risk for the pregnant 
woman and their fetus, in addition to the 
newborn baby after delivery.3,4 With the ex-
ception of infections by cytomegalovirus, the 
other diseases are routinely investigated in 
all pregnant women attending the high-risk 
pregnancy and fetal medicine unit of Hospi-
tal de Base (FUNFARME) in São José do Rio 
Preto, a reference center for the northwest 
region of São Paulo State.
Few studies have assessed the prevalence 
of the TORSCH infections among pregnant 
women in Brazil. In the north of Paraná State, 
rates of 67.0% (IgG-toxo), 1.8% (IgM-toxo), 
89.0% (IgG anti-rubella), 1.2% (IgM anti-
rubella), 1.6% (syphilis), 0.8% (hepatitis B), 
0.8% (hepatitis C) and 0.6% (HIV) were 
reported in one study.3 In the state of Mato 
Grosso do Sul, the percentages were 0.4% for 
IgM-toxo, 0.03% for IgM anti-rubella, 0.8% 
for syphilis, 0.3% for hepatitis B, 0.1% for 
hepatitis C and 0.2% for HIV.4
Recent studies with pregnant women in 
the northwest region of São Paulo State re-
ported IgG-toxo antibodies in 64.1%5 and 
1.03% of HIV seropositivity,6 but did not 
detail the results of other TORSCH infec-
tions. The aim of this study was to assess 
the prevalence of infections of the TORSCH 
group among pregnant women attending a 
university hospital.
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MATERIAL AND METHOD
Ethical considerations
This study was approved by the Research Ethics Commit-
tee of the São José do Rio Preto Medical School (FAMERP 
– protocol 168/2007). The need for a written consent of pa-
tients was waivered as all the data were retrospectively col-
lected from the patients’ hospital records.
Selection of patients’ records
A total of 624 hospital records of pregnant women who had 
attended the high-risk pregnancy and fetal medicine unit 
of Hospital de Base (FUNFARME) in São José do Rio Preto 
from January 2006 to December 2007, were included. Of 
these, 574 who had records with the necessary data to be 
retrieved for the proposal of this work were selected.
Data collection
Data were collected from records through an epidemiological 
form and later transferred to a Excel spreadsheet (version 2003).
Statistical analysis
The GraphPad Instat software version 3.06 was employed to 
calculate the rates of seropositivity for the tested infections. 
The chi-squared test was used to compare proportions; a level 
of signifi cance of 0.05 was considered statistically signifi cant.
RESULTS
The mean age selected pregnant women was 27.2 ± 6.5 years 
ranging from 13 to 44 years.
Table 1 shows the seropositivity rates for the TORSCH 
International protocol, with the exception of cytomegalo-
virus (CMV). As this test is not mandated by the Brazilian 
Health Ministry it is not performed at our institution.
Detailed information of the serological test results for 
toxoplasmosis was available for 556 pregnant women. The 
mean age of the pregnant women with risk of congenital 
transmission (n = 230; non-reagent [IgG and IgM] and rea-
gent serology for IgG + IgM) was 26.3 ± 6.6 years and for 
those without risk (n = 326; reagent serology for IgG) it was 
27.8 ± 6.4 years (p = 0.005).
Out of 465 women with available anti-rubella serologi-
cal results, the mean age of pregnant women with risk of 
congenital transmission (n = 35; non-reactive serology [IgG 
and IgM] and reactive serology for IgG + IgM) was 28.9 ± 
7.4 years and 27.1 ± 6.6 years for those without risk (n = 430; 
serology reactive for IgG; p = 0.11).
For syphilis, the mean age of the seropositive pregnant 
women was 19 ± 4.2 years and 27.2 ± 6.5 years for the seron-
egative women (p = 0.004).
The mean ages of pregnant women with and without 
HBsAg antigen were 25.3 ± 8.1 and 27.1 ± 6.5 years, respec-
tively (p = 0.37). In respect to hepatitis C, the mean ages 
were 31.7 ± 4.2 for seropositive women and 27.1 ± 6.5 years 
for seronegative women (p = 0.15).
In relation to serology for HIV, the mean age of sero-
positive pregnant women was 30.7 ± 5.4 years and 27.1 ± 
6.6 years of seronegative women (p = 0.07).
DISCUSSION
The aim of this study was to determine the prevalence 
of seropositive immunodiagnostic tests of the TORSCH 
panel group in 574 pregnant women attending a univer-
sity hospital in the northwest region of São Paulo State. 
Results of this cross-section study are representative of 
the population from the northwest region of São Paulo 
State. The observed mean age of the pregnant women was 
in line with a previous study reporting results of women 
from the same region.6
In the present study more than 60% of the pregnant 
women tested positive for IgG anti-T. gondii antibodies, 
which is in agreement with other studies carried out in 
Brazil reporting seropositivity rates ranging from 22.8% 
to 71.5%.7-12 Two recent studies performed in the north-
west region of São Paulo State found rates similar to those 
reported in the current study.5,13
Pregnant women at risk of congenital transmission 
of toxoplasmosis were younger than those without risk. 
Most humans tend to produce high-avidity anti-T. gon-
dii IgG antibodies following infection with T. gondii as a 
result of the development of immune memory.14,15 Addi-
tionally, older individuals seem to be exposed to a greater 
number of stimuli including re-infections by this para-
site, without necessarily manifesting the clinical form 
of the disease.15 Thus, we can presume that the majority 
of seropositive pregnant women are probably immune 
and with no risk of congenital transmission of T. gondii. 
Table 1. Seropositivity rates of toxoplasmosis IgG and 
IgM, rubella IgG and IgM, syphilis, hepatitis B, hepatitis 
C and HIV in pregnant women attending the Gynecol-
ogy and Obstetrics Outpatients Clinic of Hospital de 
Base (FUNFARME) in São José do Rio Preto, São Paulo 
State, Brazil from January 2006 to December 2007
Test n Seroreagent %
Toxoplasmosis   
 IgG 556 345 62.0
 IgM 556 19 3.4
Rubella   
 IgG 465 433 93.1
 IgM 465 3 0.6
Syphilis 561 5 0.9
Hepatitis B (HBsAg) 554 10 1.8
Hepatitis C (anti-HCV) 545 4 0.7
HIV1/2 531 11 2.1
Prevalence of immunodiagnostic tests among Brazilian pregnant women
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On the other hand, seronegative pregnant women or those 
seropositive for IgG and IgM are at risk of transmission 
and adequate precautions need to be taken.
Serology for rubella was performed in fewer cases, al-
though more than 93% of the pregnant women presented 
with evidence of immunization with reactivity for IgG.
In several countries, including Brazil, vaccination 
campaigns against rubella in women have contributed to 
the reduction of acute cases of the disease thereby protect-
ing susceptible patients and their fetuses.16,17 This strategy 
of increasing the immunization rates is translated in the 
high rates of IgG seropositivity seen in this study.
The percentage of pregnant women at risk for con-
genital transmission of rubella was lower than 1% and 
the mean age of these individuals was not significantly 
different from those without risk. The last vaccination 
campaign against rubella carried out in Brazil was aimed 
at women in reproductive age, i.e., between 12 and 39 
years old.18 This may explain, at least in part, the lack of 
differences in the mean ages of pregnant women with and 
without risk for congenital transmission.
The positivity rate for VDRL in this study (0.9%) was 
lower than that reported in other publications.19,20 Ado-
lescence is a phase of life in which the risk of acquiring 
sexually transmitted diseases is higher. In a study per-
formed in the state of Pará, it was observed that 15% of 
the mothers who gave birth to a baby with syphilis were 
younger than 20 years old.21,22 These data support the 
results of the current study that also found a lower mean 
age among pregnant women with positive serology for 
VDRL. Congenital syphilis is preventable; control meas-
ures adopted in Brazil aim at reducing the number of 
cases to 1 in 1,000 newborns.20
The age of pregnant women with and without reactive 
tests for hepatitis B was similar and the rate of HBsAg 
positivity (the surface antigen of the hepatitis B virus) 
was within the range for persistent infection by HBV re-
ported in Brazil. Studies performed in several states have 
demonstrated frequencies ranging between 0.3% and 
13%, including among pregnant women.3, 23-25
Previous knowledge of the serological test results 
for hepatitis B in pregnant women is of extreme im-
portance as the risks of congenital transmission in-
crease with maternal viral load. This disease should 
receive constant attention in pregnant women, as in-
fected newborn babies present a high risk of develop-
ing chronic forms of the disease due to their immuno-
logical immaturity.24, 26, 27
The frequency of anti-HCV antibodies found in 
this study is lower than that reported in the general 
population,28,29 but is close to that observed in pregnant 
women.30,31 Moreover, pregnant women, with and with-
out seropositivity had similar mean ages.
The hepatitis C virus is responsible for more than 
90% of the hepatitis previously classified as non-A and 
non-B,32 with the great majority of infected individuals 
remaining asymptomatic.33 This is of great importance, as 
pregnant women, even when asymptomatic, can transmit 
the virus to their fetuses and newborn babies.
The HIV-infection rate found in this study is elevated 
and may be related to the High-Risk Gestation Outpa-
tient Clinic being a regional reference center and that São 
José do Rio Preto is a reference center for the treatment of 
sexually transmitted diseases including AIDS.34 The mean 
ages of the pregnant women with and without anti-HIV 
antibodies were similar.
In Brazil, the National HIV/AIDS Program has in-
volved city and state governments, as well as non-gov-
ernmental organizations, in the fight against HIV/AIDS 
for more than two decades. By means of an epidemio-
logical surveillance the National Program keeps track 
of temporal and spatial trends in the occurrence of 
AIDS and HIV infection, aiming at guiding control ac-
tions of the epidemic at every level of public healthcare 
(SUS).35 Heterosexual transmission of HIV increased 
the number of infected women throughout the world, 
including in Brazil, thus raising the number of cases of 
children with AIDS due to perinatal and transplacental 
transmission.23, 36, 37
The rate of vertical transmission of HIV, with no in-
tervention, is about 25%. However, several studies have 
demonstrated a drop in transmission to 0% to 2% and a 
signifi cant reduction in the incidence of cases of AIDS in 
children, as a result of preventive measures such as the use 
of combined anti-retroviral agents, elective C-sections, the 
use of chemoprophylaxis with AZT in the perinatal period 
and restricting breastfeeding in the newborn.38-40
The results of this study underscore the importance 
of diagnosing congenitally and perinatally transmitted 
infectious-parasitic diseases for the health of pregnant 
women and their newborn babies, in agreement with 
prior publications.3,20,41 Early diagnosis allows preventive 
measures and treatment to be implemented in the ante-
natal and postnatal periods.3,4,41,42
CONCLUSIONS
In conclusion, the prevalence of the TORSCH group infec-
tions in pregnant women attending a teaching hospital are 
in agreement with those previously reported by epidemio-
logical studies and by government sources.
ETHICAL APPROVAL
This study was approved by the Research Ethics Committee 
of the Medicine School in São José do Rio Preto (FAMERP 
– protocol 168/2007).
Gonçalves, Matos, Spegiorin et al.
604
REFERENCES
1.  Madi JM, Souza RS, Araújo BF et al. Prevalence of tox-
oplasmosis, HIV, syphilis and rubella in a population 
of puerperal women using Whatman 903® filter paper. 
Braz J Infect Dis 2010; 14(1):24-9. doi: 10.1590/S1413-
86702010000100006.
2.  Duarte G. Diagnóstico e Conduta nas Infecções Ginecológicas 
e Obstétricas. Ribeirão Preto: Funpec Editora; 2003.
3.  Reiche EMV, Morimoto HK, Farias GN et al. Prevalência de 
tripanossomíase americana, sífi lis, toxoplasmose, rubéola, 
hepatite B, hepatite C e da infecção pelo vírus da imunode-
fi ciência humana, avaliada por intermédio de testes sorológi-
cos, em gestantes atendidas no período de 1996 a 1998 no Hos-
pital Universitário Regional Norte do Paraná (Universidade 
Estadual de Londrina, Paraná, Brasil). Rev Soc Bras Med Trop 
2000; 33(6): 519-27.
4.  Figueiró-Filho EA, Senefonte FRA, Lopes AHA et al. Freqüên-
cia das infecções pelo HIV-1, rubéola, sífi lis, toxoplasmose, 
citomegalovírus, herpes simples, hepatite B, hepatite C, doença 
de Chagas e HTLV I/II em gestantes, do Estado de Mato Gros-
so do Sul. Rev Soc Bras Med Trop 2007; 40(2):181-87.
5.  Rodrigues ACF, Uezato S, Vono MB et al. Associação entre 
anticorpos IgG anti-Toxoplasma gondii e os tipos sanguin-
eos ABO em gestantes. In: 44o Congresso da Sociedade Bra-
sileira de Medicina Tropical, 2008, Porto Alegre. Rev Soc 
Bras Med Trop 2008; 41(Sup):183. 
6.  Galão EA, Godoy JMP, Bagarelli LB, Perea LSA, Oliani 
AH. Epidemiological aspects of the pregant women with 
immunodeficiency virus in Brazil. Arch Med Sci 2007; 
2(2):142-44.
7.  Vaz AJ, Guerra EM, Ferratto LCC, Toledo LAS, Azevedo Neto 
RS. Sorologia positiva para sífi lis, toxoplasmose e doença de 
Chagas em gestantes de primeira consulta em centros de saúde 
de área metropolitana, Brasil. Rev Saúde Pública 1990; 24(5): 
373-79. 
8.  Cerqueira RL, Kawarabayashi M, Guimarães AC et al. Santo 
Inacio revisited: protozoan diseases in an isolated village in 
northeastern Brazil after twenty years. Am J Trop Med Hyg 
1998; 59(5):736-40. 
9.  Rey LC, Ramalho IL. Seroprevalence of toxoplasmosis in 
Fortaleza, Ceara, Brazil. Rev Inst Med Trop São Paulo 1999; 
41(3):171-4.
10. Coêlho RAL, Kobayashi M, Carvalho Jr LB. Prevalence of IgG 
antibodies specifi c to Toxoplasma gondii among blood donors 
in Recife, Northeast Brazil. Rev. Inst. Med. Trop. São Paulo 
2003; 45(4):229-31.
11. Pappas G, Roussos N, Falagas ME. Toxoplasmosis snapshots: 
Global status of Toxoplasma gondii seroprevalence and impli-
cations for pregnancy and congenital toxoplasmosis. IJP 2009; 
39:1385–94. doi:10.1016/j.ijpara.2009.04.003.
12.  Carellos EVM, Andrade GMQ, Aguiar RALP. Avaliação da apli-
cação do protocolo de triagem pré-natal para toxoplasmose 
em Belo Horizonte, Minas Gerais, Brasil: estudo transversal 
em puérperas de duas maternidades. Cad. Saúde Pública 2008; 
24(2):391-401. 
13.  Mattos CCB, Cintra JR, Ferreira AIC et al. Lack of association 
between ABO histo-blood groups, Secretor and Non-Secretor 
phenotypes, and anti-Toxoplasma gondii antibodies among 
pregnant women from the Northwestern region of Sao Paulo 
State, Brazil. Arch Med Sci 2008; 4(3):254-8.
14.  Camargo ME. Toxoplasmose. In: Ferreira AW e Ávila SLM, ed. Di-
agnóstico laboratorial das principais doenças infecciosas e auto-
imunes. Rio de Janeiro: Guanabara Koogan; 2001; pp 278-88.
15.  Frank SA. Immunology and evolution of infectious diseases. 
New Jersey: Princeton University Press; 2002. pp 348.
16.  Tookey PA, Cortina-Borja M, Peckhmam CS. Rubella sus-
ceptibility among pregnant women in North London, 1996-
1999. Journal of Public Health Medicine 2002; 24:211-6.
17.  Gutiérrez-Zufi aurre N, Hernandez JS, Muños S. Seroprevalen-
cia de anticuerpos frente a Treponema pallidum, Toxoplasma 
gondii, virus de la rubéola, virus de la hepatitis B y C y VIH 
en mujeres gestantes. Enferm Infecc Microbiol Clín 2004; 22: 
512-16.
18.  Hinman AR. Estratégia de vacinação contra a rubéola. Jornal 
de Pediatria 2007; 83(5):389-91. 
19.  Barsanti C, Valderato F, Diniz EMA, Succi RCM. Diagnóstico de 
sífi lis congênita: comparação entre testes sorológicos na mãe e 
no recém-nascido. Rev Soc Bras Med Trop 1999; 32:605-11. 
20.  Saraceni V, Domingues RMSM, Vellozo V et al. Vigilância da 
sífi lis na gravidez. Epidemiologia e Serviços de Saúde 2007; 
16(2):103-11.
21.  Araújo EC. Sífi lis congênita: Incidência em recém-nascidos. 
Jornal de Pediatria1999; 75(2):119-25.
22.  Araújo EC, Costa KSG, Silva RS, Azevedo VNG, Lima FAZ. 
Importância do pré-natal na prevenção da sífi lis congênita. 
Revista Paraense de Medicina 2006; 20(1):47-51.
23.  Bittencourt AL. Freqüência da transmissão congênita. In: Bit-
tencourt AL, ed. Infecções congênitas transplacentária. Rio de 
Janeiro: Revinter; 1995. pp 3-7.
24.  Arraes LC, Sampaio AS, Barreto S, Guilherme MAS, Lorenzato 
F. Prevalência de hepatite B em parturientes e perfi l sorológico 
perinatal. Rev Bras Ginecol Obstet 2003; 25(8):571-6. 
25.  Perim EB, Passos ADC. Hepatite B em gestantes atendidas 
pelo Programa do Pré-Natal da Secretaria Municipal de 
Saúde de Ribeirão Preto, Brasil: prevalência da infecção e 
cuidados prestados aos recém-nascidos. Rev Bras Epidemiol 
2005; 8(3):272-81. 
26.  Machado-Júnior B. Soropositividade para hepatite a vírus B em 
gestantes [dissertation]. Recife: Univ. de Pernambuco; 2000.
27.  Sociedade Brasileira de Pediatria. Documento Científi co. Con-
senso do Departamento de Gastroenterologia da Sociedade 
Brasileira de Pediatria. Hepatites Virais – Vacinas. 2004.
28.  Brito VOC, Parra D, Facchini R, Buchalla CM. Infecção pelo 
HIV, hepatites B e C e sífi lis em moradores de rua, São Paulo. 
Rev Saúde Pública 2007; 41(2):47-56. 
29.  Mello LA, Melo-Junior MR, Albuquerque ACC, Coelho MRCD. 
Soroprevalência da hepatite C em pacientes hemodialisados. 
Rev Soc Bras Med Trop 2007; 40(3):290-4. 
30.  Dias JCP. Epidemiology of Chagas disease. In: Wendel S, 
Brener Z, Camargo ME, Rassi A, ed. Chagas disease (Ameri-
can Trypanosomiaisis): its impact on transfusion and clinical 
medicine. São Paulo: ISBT Brazil 1992; pp 49-80. 
31.  Orione MAM, Assis SB, Souto FJD. Perfi l epidemiológico de 
puérperas e prevalência de anticorpos para infecção pelo HIV 
e vírus da hepatite C em Cuiabá, Mato Grosso. Rev Soc Bras 
Med Trop 2006; 39(2):163-68.
32.  Sáez-Alquezar A, Bassit L, Sabino EC. Hepatites. In: Ferreira 
AW, Ávila SLM (eds) Diagnóstico laboratorial das principais 
doenças infecciosas e auto-imunes. Rio de Janeiro: Guanabara 
Koogan; 2001. pp 47.
33.  Ferreira CT, Silveira TR. Hepatites virais: aspectos da epidemi-
ologia e da prevenção. Rev Bras Epidemiol 2004; 7(4):473-87. 
34.  São José do Rio Preto. Secretaria Municipal de Saúde e Higiene 
de São José do Rio Preto, SP. Coordenação Municipal de DST/
AIDS. Boletim Epidemiológico. Ano II n. 2. São José do Rio 
Preto – SP; 2003.
Prevalence of immunodiagnostic tests among Brazilian pregnant women
605Braz J Infect Dis 2010; 14(6):601-605
35.  Brasil. Ministério da Saúde. Coordenação Nacional de DST e 
AIDS. A Experiência do Programa Brasileiro de AIDS. Brasília, 
DF, 2002. http://www.aids.gov.br/data/documents/stored-
Documents/{B8EF5DAF-23AE-4891-AD36-1903553A3174}/
{EE03B6A9-6598-423D-BCF9-D41DBFC04408}/resp-
posit01web.pdf
36.  Swarcwald CL, Bastos FI, Esteves MAP, Andrade CLT. A dis-
seminação da epidemia de AIDS no Brasil, no período de 
1987-1996: uma análise espacial. Cad. Saúde Pública 2000; 
16(1):7-19. 
37.  Lemos LMD, Gurgel RQ, Dal Fabbro AL. Prevalência da 
infecção por HIV em parturientes de maternidades vincu-
ladas ao SUS. Rev Bras Ginecol Obstet 2005; 27(1):32-5.
38.  Castro TPT, De Lorenzi DRS, Tonin C, Zapparoli M. HIV e 
gestação. Rev. Cient. AMECS 2001; 10(1):39-46.
39.  Cardoso AJC, Griep RH, Carvalho HB, Barros A, Silva SB, 
Remien RH. Infecção pelo HIV entre gestantes atendidas nos 
centros de testagem e aconselhamento em Aids. Rev Saúde Pú-
blica 2007; 41(2):101-8. 
40.  Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. 
Recomendações para profi laxia da transmissão vertical do HIV 
e terapia anti-retroviral em gestantes. Brasília, DF, 2007.
41.  Olbrich Neto J, Meira DA. Soroprevalência de vírus lin-
fotrópico de células T humanas, vírus da imunodefi ciência 
humana, sífi lis e toxoplasmose em gestantes de Botucatu – São 
Paulo – Brasil. Fatores de risco para vírus linfotrópico de célu-
las T humanas. Rev Soc Bras Med Trop 2004; 37(1):28-32. 
42.  Santos JI, Lopes MAA, Deliège-Vasconcelos E et al. Seroprevalence 
of HIV, HTLVI/II and other perinatally-transmitted pathogens in 
Salvador, Bahia. Rev Inst Med Trop São Paulo 1995; 37(4):343-8. 
Gonçalves, Matos, Spegiorin et al.
